ArticleCancer immunology, immunotherapy : CII2020
Open access · greenAbstract read
In one paragraph
Article in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 28 citations in OpenAlex.
- Integrating Lymph Node Metastasis and Programmed Death-Ligand 1 Prediction in Non-Small Cell Lung Cancer From a Single PET/CT Scan: Multicenter Radiomics Study.JMIR medical informatics · 2026Article
- Abbreviated dynamic total-body [Quantitative imaging in medicine and surgery · 2025Article
- Assessment of tertiary lymphoid structures viaCancer immunology, immunotherapy : CII · 2025Article
- The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients.Frontiers in oncology · 2025Article
- Repeated dynamic [European journal of nuclear medicine and molecular imaging · 2024Observational
- Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights.Nature communications · 2024Article
- Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept.Cell reports. Medicine · 2024Article
- Combination of tumor asphericity and an extracellular matrix-related prognostic gene signature in non-small cell lung cancer patients.Scientific reports · 2023Article
- Unique Metabolic Contexts Sensitize Cancer Cells and Discriminate between Glycolytic Tumor Types.Cancers · 2023Article
- The value of preoperative positron emission tomography/computed tomography in differentiating the invasive degree of hypometabolic lung adenocarcinoma.BMC medical imaging · 2023Article
- Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives.Cancer innovation · 2023Review
- Imaging glucose metabolism to reveal tumor progression.Frontiers in physiology · 2023Review
- Radiomic Signatures Associated with CD8Cancers · 2022Review
- eIF6 is potential diagnostic and prognostic biomarker that associated withJournal of translational medicine · 2022Article
- Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy.Frontiers in immunology · 2022Review
- Investigating the association between ground-glass nodules glucose metabolism and the invasive growth pattern of early lung adenocarcinoma.Quantitative imaging in medicine and surgery · 2021Article
- Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2021Article
- Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status.Scientific reports · 2021Article
- Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 3 institutions in 2 countries.
Kyle G MitchellDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Behrang AminiDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yunfei WangDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Brett W CarterDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Myrna C B GodoyDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Edwin R ParraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carmen BehrensDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX, 77030, USA.
Pamela VillalobosDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alexandre ReubenDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX, 77030, USA.
J Jack LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Annikka WeissferdtDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cesar A MoranDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Junya FujimotoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Boris SepesiDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Garrett L WalshDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ara A VaporciyanDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wayne L HofstetterDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
William N WilliamDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX, 77030, USA.
Don L GibbonsDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX, 77030, USA.
Jing WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patrick HwuDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stephen G SwisherDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David Piwnica-WormsDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Humam KadaraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX, 77030, USA.
Weiyi PengDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. wpeng2@central.uh.edu.
Tina CasconeDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX, 77030, USA. tcascone@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USBeneficência Portuguesa de São Paulo · BRUniversity of Houston · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4MThe University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL · 2019 to 2023
$10.3MThe role of the PI3K pathway in immune resistanceR01CA187076 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL, HWU, PATRICK · 2014 to 2018
$2.0MBiomarkers and Resistance Mechanisms in Melanoma T-cell TherapyR01CA184845 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HWU, PATRICK, MULE, JAMES J. · 2014 to 2018
$1.7MCancer Prevention and Research Institute of Texa RP170401Conquer Cancer Foundation (ASCO 2018 Career Development Award) 12895DoD PROSPECT Grant W81XWH-07-1-0306Khalifa Bin Zayed Al Nahyan Foundation Khalifa Scholar AwardLung SPORE 5 P50 CA070907MD Anderson Cancer Center Support Grant P30CA01667NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS P50 CA221703NCI NIH HHS R01 CA184845NCI NIH HHS R01 CA187076
Abstract
Enhanced tumor glycolytic activity is a mechanism by which tumors induce an immunosuppressive environment to resist adoptive T cell therapy; therefore, methods of assessing intratumoral glycolytic activity are of considerable clinical interest. In this study, we characterized the relationships among tumor
Indexed as
B7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungFluorodeoxyglucose F18GlycolysisHumansLung NeoplasmsLymphocytes, Tumor-InfiltratingPositron-Emission TomographyPrognosisRadiopharmaceuticalsRetrospective StudiesSurvival RateTranscriptomeTumor MicroenvironmentB7-H1 AntigenBiomarkers, TumorCD274 protein, humanFluorodeoxyglucose F18RadiopharmaceuticalsPositron emission tomographyResected non-small cell lung cancerTumor glycolysisTumor immunometabolic phenotypes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.